NO20002001D0 - Peptider i stand til õ inhibere interaksjonen mellom preseniliner og <beta>-amyloidpeptidet eller dettes forløper - Google Patents
Peptider i stand til õ inhibere interaksjonen mellom preseniliner og <beta>-amyloidpeptidet eller dettes forløperInfo
- Publication number
- NO20002001D0 NO20002001D0 NO20002001A NO20002001A NO20002001D0 NO 20002001 D0 NO20002001 D0 NO 20002001D0 NO 20002001 A NO20002001 A NO 20002001A NO 20002001 A NO20002001 A NO 20002001A NO 20002001 D0 NO20002001 D0 NO 20002001D0
- Authority
- NO
- Norway
- Prior art keywords
- presenilines
- precursor
- beta
- inhibiting
- interaction
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9713384A FR2770217B1 (fr) | 1997-10-24 | 1997-10-24 | Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide |
| US9567198P | 1998-08-07 | 1998-08-07 | |
| PCT/FR1998/002278 WO1999021886A1 (fr) | 1997-10-24 | 1998-10-23 | PEPTIDES CAPABLES D'INHIBER L'INTERACTION ENTRE LES PRESENILINES ET LE PEPTIDE β-AMYLOIDE OU SON PRECURSEUR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002001L NO20002001L (no) | 2000-04-17 |
| NO20002001D0 true NO20002001D0 (no) | 2000-04-17 |
| NO328908B1 NO328908B1 (no) | 2010-06-14 |
Family
ID=26233891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002001A NO328908B1 (no) | 1997-10-24 | 2000-04-17 | In vitro anvendelse av et polypeptid som er i stand til a inhibere interaksjonen mellom preseniliner og APP. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1025121B1 (no) |
| JP (1) | JP2001521043A (no) |
| KR (1) | KR100626475B1 (no) |
| CN (1) | CN100429230C (no) |
| AU (1) | AU766522B2 (no) |
| BR (1) | BR9813105A (no) |
| CA (1) | CA2305816C (no) |
| CY (1) | CY1112236T1 (no) |
| CZ (1) | CZ303226B6 (no) |
| HU (1) | HU227660B1 (no) |
| IL (2) | IL135751A0 (no) |
| NO (1) | NO328908B1 (no) |
| WO (1) | WO1999021886A1 (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227660B1 (en) * | 1997-10-24 | 2011-10-28 | Aventis Pharma Sa | Process and test for detecting of compounds capable of inhibiting this interaction between presenilins and the betha-amyloid peptide or its precursor |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| AU2001233955A1 (en) * | 2000-02-24 | 2001-09-03 | Oxford Glycosciences (Uk) Limited | Diagnosis and treatment of bipolar affective disorder |
| CA2441165A1 (en) * | 2001-03-16 | 2002-09-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of binding domains of presenilins and transmembrane proteins for drug screening |
| CA2641555A1 (en) * | 2006-02-06 | 2007-08-16 | Elan Pharmaceuticals, Inc. | Preferential inhibition of presenilin-1 |
| US8129334B2 (en) * | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
| AU2007241056A1 (en) * | 2006-03-31 | 2007-11-01 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory |
| ES2530141B1 (es) * | 2013-08-26 | 2016-01-15 | Juan Carlos GALLAR RUIZ | Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad. |
| CN108860921B (zh) | 2018-08-08 | 2020-11-20 | 上海鸿研物流技术有限公司 | 可折叠容器 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0568575B2 (en) * | 1991-01-21 | 2010-11-03 | Elan Pharmaceuticals, Inc. | Test and model for alzheimer's disease |
| US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
| AU732508B2 (en) * | 1996-01-26 | 2001-04-26 | Governing Council Of The University Of Toronto, The | Nucleic acids and proteins related to Alzheimer's disease, and uses therefor |
| HU227660B1 (en) * | 1997-10-24 | 2011-10-28 | Aventis Pharma Sa | Process and test for detecting of compounds capable of inhibiting this interaction between presenilins and the betha-amyloid peptide or its precursor |
-
1998
- 1998-10-23 HU HU0004605A patent/HU227660B1/hu not_active IP Right Cessation
- 1998-10-23 BR BR9813105-2A patent/BR9813105A/pt not_active IP Right Cessation
- 1998-10-23 EP EP98951547A patent/EP1025121B1/fr not_active Expired - Lifetime
- 1998-10-23 IL IL13575198A patent/IL135751A0/xx unknown
- 1998-10-23 KR KR1020007004298A patent/KR100626475B1/ko not_active Expired - Fee Related
- 1998-10-23 WO PCT/FR1998/002278 patent/WO1999021886A1/fr not_active Ceased
- 1998-10-23 CZ CZ20001462A patent/CZ303226B6/cs not_active IP Right Cessation
- 1998-10-23 CN CNB98810508XA patent/CN100429230C/zh not_active Expired - Fee Related
- 1998-10-23 CA CA2305816A patent/CA2305816C/fr not_active Expired - Fee Related
- 1998-10-23 JP JP2000517994A patent/JP2001521043A/ja active Pending
-
2000
- 2000-04-17 NO NO20002001A patent/NO328908B1/no not_active IP Right Cessation
- 2000-04-19 IL IL135751A patent/IL135751A/en not_active IP Right Cessation
- 2000-05-03 AU AU31295/00A patent/AU766522B2/en not_active Ceased
-
2011
- 2011-11-24 CY CY20111101152T patent/CY1112236T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010024541A (ko) | 2001-03-26 |
| NO20002001L (no) | 2000-04-17 |
| CZ20001462A3 (cs) | 2000-10-11 |
| CY1112236T1 (el) | 2015-12-09 |
| AU766522B2 (en) | 2003-10-16 |
| HU227660B1 (en) | 2011-10-28 |
| IL135751A (en) | 2010-12-30 |
| CN1277616A (zh) | 2000-12-20 |
| CA2305816C (fr) | 2012-07-10 |
| HUP0004605A3 (en) | 2002-09-30 |
| HUP0004605A1 (hu) | 2001-04-28 |
| EP1025121A1 (fr) | 2000-08-09 |
| KR100626475B1 (ko) | 2006-09-20 |
| EP1025121B1 (fr) | 2011-08-24 |
| JP2001521043A (ja) | 2001-11-06 |
| WO1999021886A1 (fr) | 1999-05-06 |
| AU3129500A (en) | 2000-12-14 |
| CZ303226B6 (cs) | 2012-06-06 |
| BR9813105A (pt) | 2000-08-15 |
| NO328908B1 (no) | 2010-06-14 |
| IL135751A0 (en) | 2001-05-20 |
| CN100429230C (zh) | 2008-10-29 |
| CA2305816A1 (fr) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237348T1 (de) | Flüssige gonadotropinhaltige arzneimittel | |
| FI956310L (fi) | Stabiloidut farmaseuttiset peptidikoostumukset | |
| DK0833649T4 (da) | Proteinhydrolysatpræparater til forebyggelse eller behandling af allergier | |
| DE69825526D1 (de) | Korrektur der vorgegebenen Zeit | |
| BR9607317A (pt) | Peptídios e composição farmacêutica | |
| BR9607318A (pt) | Peptidos e composição farmacêutica | |
| ID23151A (id) | Preparat obat yang mengandung gas mulia lipofilik | |
| DK6893D0 (da) | Peptid | |
| ID19305A (id) | Formulasi peptida berair | |
| ID24520A (id) | Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya | |
| EP1021202A4 (en) | IMMUNOGENIC PEPTIDES FROM HPV E7 PROTEIN | |
| NO995500L (no) | Anvendelse av en farmasøytisk sammensetning til behandling av/eller forhindring av ischemi | |
| NO985680D0 (no) | Peptidderivater | |
| LV10962A (lv) | Jauni peptidi | |
| DE69705628D1 (de) | Chlorfluorkohlenwasserstoff freie aerosol-arzneizubereitungen enthaltend mometasonfuroat | |
| NO20002001D0 (no) | Peptider i stand til õ inhibere interaksjonen mellom preseniliner og <beta>-amyloidpeptidet eller dettes forløper | |
| NO983849L (no) | Peptidderivater | |
| IT1283772B1 (it) | Procedimento per la preparazione di reina e diacereina | |
| DK1047445T3 (da) | Modificerede enzymer og anvendelse heraf til peptidsyntese | |
| NO20000575D0 (no) | Rekombinant ekspresjon av insulin C-peptid | |
| DK1222921T3 (da) | Farmaceutiske sammensætninger indeholdende tizoxanid og/eller nitazoxanid | |
| BR9709406B1 (pt) | fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas. | |
| DE69427363D1 (de) | Plättchenaggregationsinhibierende peptide | |
| ID21131A (id) | Kompresor jenis lempeng dorong | |
| DE69720266D1 (de) | Vielfältig verzweigte peptidkonstruktionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |